Safety and Efficacy Assessment of Bacteriophages Isolated from Kibera, Kenya Wastewater Plant, against Multidrug-Resistant Pseudomonas aeruginosa Infection in BALB/c Mice

Meshack Tweya Omwega^{1, 2,} , John M. Maingi¹, Anthony Kebira Nyamache¹ and Atunga Nyachieo²

¹Department of Biochemistry, Microbiology and Biotechnology, Kenyatta University, Nairobi, Kenya

²Department of Reproductive Health Biology, Institute of Primate Research, Nairobi, Kenya

Cite this paper:
Meshack Tweya Omwega, John M. Maingi, Anthony Kebira Nyamache and Atunga Nyachieo. Safety and Efficacy Assessment of Bacteriophages Isolated from Kibera, Kenya Wastewater Plant, against Multidrug-Resistant Pseudomonas aeruginosa Infection in BALB/c Mice. American Journal of Infectious Diseases and Microbiology. 2022; 10(1):11-21. doi: 10.12691/ajidm-10-1-3

Abstract

Pseudomonas aeruginosa is a pathogen of great clinical importance to both humans and animals. It causes pneumonia in cystic fibrosis patients, and it is responsible for the infections of blood and lungs during surgery. Increased antibiotic use has led to the emergence of multidrug-resistant strains of P. aeruginosa. Recently, phage therapy has attracted much attention as a promising alternative against the increasing antimicrobial resistance. This study determined the safety and efficacy of phage therapy against virulent P. aeruginosa in a murine model. Phage PaCIKb2 was isolated from sewage water. Morphological characterization by transmission electron microscope was done. We assessed the phages' antimicrobial effect in vitro and in biofilms, its growth kinetics, host ranges, temperature and pH stability. Therapeutic safety and efficacy were observed 24 hours post-infection with virulent P. aeruginosa in a murine model. Transmission Electron Microscopy revealed phage PaCIKb2 to belong to the family myoviridae. The phage was found to be high temperature tolerant (up to 50°C). It was active between pH ranges (5 and 11), had a latent period of 15 minutes with a burst size of 316 viral particles, and exhibited a narrow host range. After intravenous phage administration dose (2×10⁹ PFU/ml) post-infection with virulent P. aeruginosa, the presence of phages in vivo and reduction of bacterial loads in mice was observed. A reduction in mice tissue inflammation suggested the effectiveness of phage PaCIKb2 phage therapy. This research gives data that supports the use of phage therapy against multidrug-resistant P. aeruginosa.

Keywords:
phage therapy MDR-PA Bacteriophage (Phage) Pseudomonas aeruginosa antimicrobial resistance multi-drug resistance

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Figures

References:

[1]	H. Fazeli, R. Akbari, S. Moghim, T. Narimani, M. R. Arabestani, and A. R. Ghoddousi, “Pseudomonas aeruginosa infections in patients, hospital means, and personnel’s specimens,” 2012. [Online]. Available: www.mui.ac.ir.
[2]	C. Mesquita, P. Soares-Castro, and P. Santos, “Pseudomonas aeruginosa: phenotypic flexibility and antimicrobial resistance,” undefined, 2013.
[3]	T. Strateva and D. Yordanov, “Pseudomonas aeruginosa - A phenomenon of bacterial resistance,” Journal of Medical Microbiology, vol. 58, no. 9. J Med Microbiol, pp. 1133-1148, Sep. 2009.
[4]	W. H. Zhao and Z. Q. Hu, “β-Lactamases identified in clinical isolates of Pseudomonas aeruginosa,” Critical Reviews in Microbiology, vol. 36, no. 3. pp. 245-258, Aug. 2010.
[5]	J. K. Akhwale et al., “Isolation, characterization and analysis of bacteriophages from the haloalkaline lake Elmenteita, Kenya,” PLoS One, 2019.
[6]	M. Chatterjee, C. P. Anju, L. Biswas, V. Anil Kumar, C. Gopi Mohan, and R. Biswas, “Antibiotic resistance in Pseudomonas aeruginosa and alternative therapeutic options,” International Journal of Medical Microbiology. 2016.
[7]	J. M. Ochieng’Oduor, N. Onkoba, F. Maloba, W. O. Arodi, and A. Nyachieo, “Efficacy of lytic staphylococcus aureus bacteriophage against multidrug-resistant staphylococcus aureus in mice,” J. Infect. Dev. Ctries., 2016.
[8]	A. Dydecka et al., “The ea22 gene of lambdoid phages: preserved prolysogenic function despite of high sequence diversity,” Virus Genes, vol. 56, no. 2, pp. 266-277, Apr. 2020.
[9]	F. Cao et al., “Evaluation of the efficacy of a bacteriophage in the treatment of pneumonia induced by multidrug resistance Klebsiella pneumoniae in mice,” Biomed Res. Int., vol. 2015, 2015.
[10]	S. M. Sillankorva, H. Oliveira, and J. Azeredo, “Bacteriophages and their role in food safety,” International Journal of Microbiology. 2012.
[11]	W. N. Arifin and W. M. Zahiruddin, “Sample Size Calculation in Animal Studies Using Resource Equation Approach,” Malays J Med Sci, vol. 24, no. 5, pp. 101-105.
[12]	B. Biswas et al., “Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium,” Infect. Immun., vol. 70, no. 1, pp. 204-210, 2002.
[13]	T. Anand et al., “Phage therapy for treatment of virulent Klebsiella pneumoniae infection in a mouse model,” J. Glob. Antimicrob. Resist., vol. 21, pp. 34-41, Jun. 2020.
[14]	A. Revelas, “Healthcare - associated infections: A public health problem,” Niger. Med. J., vol. 53, no. 2, p. 59, 2012.
[15]	X. Wittebole, S. De Roock, and S. M. Opal, “A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens,” Virulence, vol. 5, no. 1. Taylor and Francis Inc., pp. 226-235, 2014.
[16]	H. W. Ackermann, “5500 Phages examined in the electron microscope,” Archives of Virology, vol. 152, no. 2. pp. 227-243, Feb. 2007.
[17]	D. R. Harper and M. C. Enright, “Bacteriophages for the treatment of Pseudomonas aeruginosa infections,” Journal of Applied Microbiology, vol. 111, no. 1. J Appl Microbiol, pp. 1-7, Jul. 2011.
[18]	P. Speck and A. Smithyman, “Safety and efficacy of phage therapy via the intravenous route,” FEMS Microbiol. Lett., vol. 363, no. 3, Dec. 2015.
[19]	D. Maura, E. Morello, L. du Merle, P. Bomme, C. Le Bouguénec, and L. Debarbieux, “Intestinal colonization by enteroaggregative Escherichia coli supports long-term bacteriophage replication in mice,” Environ. Microbiol., vol. 14, no. 8, pp. 1844-1854, Aug. 2012.
[20]	R. Watanabe et al., “Efficacy of bacteriophage therapy against gut-derived sepsis caused by Pseudomonas aeruginosa in mice,” Antimicrob. Agents Chemother., 2007.